Monthly
US$200
Billed every month
Pregabalin Capsules(普瑞巴林胶囊)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders34View records ↓
Under-review filings12View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers70View records ↓
API companies with A status25View records ↓
Chemical-drug catalogue
Loaded records: 34 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 32 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 东北制药集团沈阳第一制药有限公司 | 东北制药集团沈阳第一制药有限公司 | 国药准字H20264982 | 2026/06/30 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 东北制药集团沈阳第一制药有限公司 | 东北制药集团沈阳第一制药有限公司 | 国药准字H20264983 | 2026/06/30 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 晖致制药（大连）有限公司 | 晖致制药（大连）有限公司 | 国药准字H20263111 | 2026/01/14 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 晖致制药（大连）有限公司 | 晖致制药（大连）有限公司 | 国药准字H20263112 | 2026/01/14 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 大桐制药（中国）有限责任公司 | 大桐制药（中国）有限责任公司 | 国药准字H20253195 | 2025/01/14 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 大桐制药（中国）有限责任公司 | 大桐制药（中国）有限责任公司 | 国药准字H20253194 | 2025/01/14 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江昂利康制药股份有限公司 | 浙江昂利康制药股份有限公司 | 国药准字H20253180 | 2025/01/14 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江昂利康制药股份有限公司 | 浙江昂利康制药股份有限公司 | 国药准字H20253179 | 2025/01/14 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南赛隆药业有限公司 | 湖南赛隆药业（长沙）有限公司 | 国药准字H20247280 | 2024/11/07 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建省宝诺医药研发有限公司 | 石家庄市华新药业有限责任公司 | 国药准字H20249116 | 2024/10/22 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建省宝诺医药研发有限公司 | 石家庄市华新药业有限责任公司 | 国药准字H20249115 | 2024/10/22 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽九洲方圆制药有限公司 | 安徽九洲方圆制药有限公司 | 国药准字H20249082 | 2024/10/16 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏恩华药业股份有限公司 | 江苏恩华药业股份有限公司 | 国药准字H20243979 | 2024/06/11 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新华制药股份有限公司 | 山东新华制药股份有限公司 | 国药准字H20243977 | 2024/06/11 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新华制药股份有限公司 | 山东新华制药股份有限公司 | 国药准字H20243976 | 2024/06/11 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波双成药业有限公司 | 宁波双成药业有限公司 | 国药准字H20243330 | 2024/03/12 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波双成药业有限公司 | 宁波双成药业有限公司 | 国药准字H20243331 | 2024/03/12 | 300mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 澳美制药（海南）有限公司 | 澳美制药（海南）有限公司 | 国药准字H20243329 | 2024/03/12 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 澳美制药（海南）有限公司 | 澳美制药（海南）有限公司 | 国药准字H20243328 | 2024/03/12 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆医药（集团）股份有限公司 | 重庆科瑞制药（集团）有限公司 | 国药准字H20243304 | 2024/03/05 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆医药（集团）股份有限公司 | 重庆科瑞制药（集团）有限公司 | 国药准字H20243305 | 2024/03/05 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20243210 | 2024/02/23 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20243211 | 2024/02/23 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南赛隆药业有限公司 | 湖南赛隆药业（长沙）有限公司 | 国药准字H20243261 | 2024/02/23 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20234482 | 2023/11/14 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东丹红制药有限公司 | 山东步长制药股份有限公司 | 国药准字H20234016 | 2023/08/08 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东丹红制药有限公司 | 山东步长制药股份有限公司 | 国药准字H20234017 | 2023/08/08 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Dr. Reddy’s Laboratories Limited | Dr. Reddy’s Laboratories Limited | 国药准字HJ20230097 | 2023/08/01 | 75mg | Not stated by source | CDE |
| Dr. Reddy’s Laboratories Limited | Dr. Reddy’s Laboratories Limited | 国药准字HJ20230098 | 2023/08/01 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川制药制剂有限公司 | 四川制药制剂有限公司 | 国药准字H20233922 | 2023/07/11 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川制药制剂有限公司 | 四川制药制剂有限公司 | 国药准字H20233923 | 2023/07/11 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆药友制药有限责任公司 | 重庆药友制药有限责任公司 | 国药准字H20233557 | 2023/05/19 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆药友制药有限责任公司 | 重庆药友制药有限责任公司 | 国药准字H20233558 | 2023/05/19 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 德全药品（江苏）股份有限公司 | 德全药品（江苏）股份有限公司 | 国药准字H20233255 | 2023/03/07 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东金城金素制药有限公司 | 上海金城素智药业有限公司 | 国药准字H20233167 | 2023/02/14 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东金城金素制药有限公司 | 上海金城素智药业有限公司 | 国药准字H20233165 | 2023/02/14 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东金城金素制药有限公司 | 上海金城素智药业有限公司 | 国药准字H20233166 | 2023/02/14 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川科伦药物研究院有限公司 | 四川科伦药业股份有限公司 | 国药准字H20233134 | 2023/02/07 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川科伦药物研究院有限公司 | 四川科伦药业股份有限公司 | 国药准字H20233133 | 2023/02/07 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 亚宝药业太原制药有限公司 | 亚宝药业太原制药有限公司 | 国药准字H20223957 | 2022/12/30 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 亚宝药业太原制药有限公司 | 亚宝药业太原制药有限公司 | 国药准字H20223958 | 2022/12/30 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东九瑞科技开发有限公司 | 浙江京新药业股份有限公司 | 国药准字H20223713 | 2022/09/30 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东九瑞科技开发有限公司 | 浙江京新药业股份有限公司 | 国药准字H20223712 | 2022/09/30 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 扬子江药业集团南京海陵药业有限公司 | 扬子江药业集团南京海陵药业有限公司 | 国药准字H20223587 | 2022/08/10 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 扬子江药业集团南京海陵药业有限公司 | 扬子江药业集团南京海陵药业有限公司 | 国药准字H20223588 | 2022/08/10 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天地恒一制药股份有限公司 | 天地恒一制药股份有限公司 | 国药准字H20223305 | 2022/05/10 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天地恒一制药股份有限公司 | 天地恒一制药股份有限公司 | 国药准字H20223306 | 2022/05/10 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天地恒一制药股份有限公司 | 天地恒一制药股份有限公司 | 国药准字H20223307 | 2022/05/10 | 300mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南锦瑞制药有限公司 | 海南锦瑞制药有限公司 | 国药准字H20223220 | 2022/04/12 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江华海药业股份有限公司 | 浙江华海药业股份有限公司 | 国药准字H20213765 | 2021/09/30 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江华海药业股份有限公司 | 浙江华海药业股份有限公司 | 国药准字H20213766 | 2021/09/30 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江华海药业股份有限公司 | 浙江华海药业股份有限公司 | 国药准字H20213767 | 2021/09/30 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄龙泽制药股份有限公司 | 石家庄龙泽制药股份有限公司 | 国药准字H20213706 | 2021/09/07 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄龙泽制药股份有限公司 | 石家庄龙泽制药股份有限公司 | 国药准字H20213703 | 2021/09/07 | 25mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄龙泽制药股份有限公司 | 石家庄龙泽制药股份有限公司 | 国药准字H20213702 | 2021/09/07 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄龙泽制药股份有限公司 | 石家庄龙泽制药股份有限公司 | 国药准字H20213705 | 2021/09/07 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄龙泽制药股份有限公司 | 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 2021/09/07 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团欧意药业有限公司 | 石药集团欧意药业有限公司 | 国药准字H20213449 | 2021/06/01 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团欧意药业有限公司 | 石药集团欧意药业有限公司 | 国药准字H20213450 | 2021/06/01 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南万玮制药有限公司 | 海南万玮制药有限公司 | 国药准字H20213340 | 2021/05/11 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南万玮制药有限公司 | 海南万玮制药有限公司 | 国药准字H20213339 | 2021/05/11 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波科尔康美诺华药业有限公司 | 宁波美诺华天康药业有限公司 | 国药准字H20203640 | 2020/12/02 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波科尔康美诺华药业有限公司 | 宁波美诺华天康药业有限公司 | 国药准字H20203641 | 2020/12/02 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆赛维药业有限公司 | 重庆赛维药业有限公司 | 国药准字H20130064 | 2020/11/11 | 100mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 重庆赛维药业有限公司 | 重庆赛维药业有限公司 | 国药准字H20130073 | 2020/11/11 | 75mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 华润双鹤药业股份有限公司 | 华润双鹤药业股份有限公司 | 国药准字H20203551 | 2020/11/04 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华润双鹤药业股份有限公司 | 华润双鹤药业股份有限公司 | 国药准字H20203550 | 2020/11/04 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 齐鲁制药（海南）有限公司 | 国药准字H20203041 | 2020/02/20 | 150mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 齐鲁制药（海南）有限公司 | 国药准字H20203040 | 2020/02/20 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Pfizer Limited | Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg | H20150625 | 2010/05/07 | 300mg | Imported originator drug (进口原研药品) | CDE |
| Pfizer Limited | Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg | H20150624 | 2010/05/07 | 200mg | Imported originator drug (进口原研药品) | CDE |
| Pfizer Limited | Pfizer Manufacturing Deutschland GmbH,Betriebsstatte Freiburg | H20150622 | 2010/05/07 | 150mg | Imported originator drug (进口原研药品) | CDE |
| Pfizer Limited | Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg | H20150621 | 2010/05/07 | 100mg | Imported originator drug (进口原研药品) | CDE |
| Pfizer Limited | Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg | H20150619 | 2010/05/07 | 75mg | Imported originator drug (进口原研药品) | CDE |
| Pfizer Limited | Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg | H20150618 | 2010/05/07 | 50mg | Imported originator drug (进口原研药品) | CDE |
| Pfizer Limited | Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg | H20150617 | 2010/05/07 | 25mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 70 distinct approval numbers and 32 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 重庆医药(集团)股份有限公司 | 国药准字H20243304 | 75mg | Category B (乙) | XN02BGP112E001010101016 | NHSA |
| 重庆赛维药业有限公司 | 国药准字H20130064 | 100mg | Category B (乙) | XN02BGP112E001010101028 | NHSA |
| 湖南洞庭药业股份有限公司 | 国药准字H20233557 | 75mg | Category B (乙) | XN02BGP112E001010101066 | NHSA |
| Upjohn EESV | 国药准字J20160022 | 150mg | Category B (乙) | XN02BGP112E001010101187 | NHSA |
| 江苏恩华药业股份有限公司 | 国药准字H20243979 | 75mg | Category B (乙) | XN02BGP112E001010101435 | NHSA |
| 扬子江药业集团南京海陵药业有限公司 | 国药准字H20223588 | 75mg | Category B (乙) | XN02BGP112E001010101748 | NHSA |
| 德全药品(江苏)股份有限公司 | 国药准字H20233255 | 75mg | Category B (乙) | XN02BGP112E001010101751 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20233133 | 75mg | Category B (乙) | XN02BGP112E001010102180 | NHSA |
| 四川制药制剂有限公司 | 国药准字H20233922 | 75mg | Category B (乙) | XN02BGP112E001010102297 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20213449 | 75mg | Category B (乙) | XN02BGP112E001010102770 | NHSA |
| 亚宝药业集团股份有限公司 | 国药准字H20223957 | 75mg | Category B (乙) | XN02BGP112E001010102987 | NHSA |
| 山东丹红制药有限公司 | 国药准字H20234016 | 75mg | Category B (乙) | XN02BGP112E001010104073 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20243976 | 150mg | Category B (乙) | XN02BGP112E001010104187 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203641 | 75mg | Category B (乙) | XN02BGP112E001010104565 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20253180 | 75mg | Category B (乙) | XN02BGP112E001010104606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213765 | 75mg | Category B (乙) | XN02BGP112E001010104647 | NHSA |
| 广东九瑞科技开发有限公司 | 国药准字H20223712 | 75mg | Category B (乙) | XN02BGP112E001010104658 | NHSA |
| 澳美制药(海南)有限公司 | 国药准字H20243328 | 150mg | Category B (乙) | XN02BGP112E001010105760 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20203040 | 75mg | Category B (乙) | XN02BGP112E001010105847 | NHSA |
| Dr.Reddy's Laboratories Limited | 国药准字HJ20230097 | 75mg | Category B (乙) | XN02BGP112E001010178377 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213703 | 25mg | Category B (乙) | XN02BGP112E001010179261 | NHSA |
| 海南锦瑞制药有限公司 | 国药准字H20223220 | 75mg | Category B (乙) | XN02BGP112E001010179280 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001010179286 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20223305 | 75mg | Category B (乙) | XN02BGP112E001010180086 | NHSA |
| 大桐制药(中国)有限责任公司 | 国药准字H20253194 | 75mg | Category B (乙) | XN02BGP112E001010180685 | NHSA |
| 广东金城金素制药有限公司 | 国药准字H20233167 | 75mg | Category B (乙) | XN02BGP112E001010181274 | NHSA |
| 安徽九洲方圆制药有限公司 | 国药准字H20249082 | 75mg | Category B (乙) | XN02BGP112E001010181400 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20203550 | 75mg | Category B (乙) | XN02BGP112E001010181661 | NHSA |
| 广东金城金素制药有限公司 | 国药准字H20233165 | 150mg | Category B (乙) | XN02BGP112E001010181979 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213339 | 75mg | Category B (乙) | XN02BGP112E001010182249 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243211 | 75mg | Category B (乙) | XN02BGP112E001010183521 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20233134 | 150mg | Category B (乙) | XN02BGP112E001010183542 | NHSA |
| 福建省宝诺医药研发有限公司 | 国药准字H20249115 | 75mg | Category B (乙) | XN02BGP112E001010183544 | NHSA |
| 重庆医药(集团)股份有限公司 | 国药准字H20243305 | 150mg | Category B (乙) | XN02BGP112E001010183661 | NHSA |
| 宁波双成药业有限公司 | 国药准字H20243330 | 75mg | Category B (乙) | XN02BGP112E001010184155 | NHSA |
| 湖南洞庭药业股份有限公司 | 国药准字H20233557 | 75mg | Category B (乙) | XN02BGP112E001010201066 | NHSA |
| Upjohn EESV | 国药准字J20160022 | 150mg | Category B (乙) | XN02BGP112E001010201187 | NHSA |
| 扬子江药业集团南京海陵药业有限公司 | 国药准字H20223588 | 75mg | Category B (乙) | XN02BGP112E001010201748 | NHSA |
| 德全药品(江苏)股份有限公司 | 国药准字H20233255 | 75mg | Category B (乙) | XN02BGP112E001010201751 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20233133 | 75mg | Category B (乙) | XN02BGP112E001010202180 | NHSA |
| 四川制药制剂有限公司 | 国药准字H20233922 | 75mg | Category B (乙) | XN02BGP112E001010202297 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20213449 | 75mg | Category B (乙) | XN02BGP112E001010202770 | NHSA |
| 亚宝药业集团股份有限公司 | 国药准字H20223957 | 75mg | Category B (乙) | XN02BGP112E001010202987 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203641 | 75mg | Category B (乙) | XN02BGP112E001010204565 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20253180 | 75mg | Category B (乙) | XN02BGP112E001010204606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213765 | 75mg | Category B (乙) | XN02BGP112E001010204647 | NHSA |
| 广东九瑞科技开发有限公司 | 国药准字H20223712 | 75mg | Category B (乙) | XN02BGP112E001010204658 | NHSA |
| 澳美制药(海南)有限公司 | 国药准字H20243328 | 150mg | Category B (乙) | XN02BGP112E001010205760 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20203040 | 75mg | Category B (乙) | XN02BGP112E001010205847 | NHSA |
| Dr.Reddy's Laboratories Limited | 国药准字HJ20230097 | 75mg | Category B (乙) | XN02BGP112E001010278377 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213703 | 25mg | Category B (乙) | XN02BGP112E001010279261 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001010279286 | NHSA |
| 广东金城金素制药有限公司 | 国药准字H20233167 | 75mg | Category B (乙) | XN02BGP112E001010281274 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20203550 | 75mg | Category B (乙) | XN02BGP112E001010281661 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243211 | 75mg | Category B (乙) | XN02BGP112E001010283521 | NHSA |
| 福建省宝诺医药研发有限公司 | 国药准字H20249115 | 75mg | Category B (乙) | XN02BGP112E001010283544 | NHSA |
| 重庆医药(集团)股份有限公司 | 国药准字H20243305 | 150mg | Category B (乙) | XN02BGP112E001010283661 | NHSA |
| 湖南洞庭药业股份有限公司 | 国药准字H20233557 | 75mg | Category B (乙) | XN02BGP112E001010301066 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20233133 | 75mg | Category B (乙) | XN02BGP112E001010302180 | NHSA |
| 四川制药制剂有限公司 | 国药准字H20233922 | 75mg | Category B (乙) | XN02BGP112E001010302297 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203641 | 75mg | Category B (乙) | XN02BGP112E001010304565 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20253180 | 75mg | Category B (乙) | XN02BGP112E001010304606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213765 | 75mg | Category B (乙) | XN02BGP112E001010304647 | NHSA |
| 广东九瑞科技开发有限公司 | 国药准字H20223712 | 75mg | Category B (乙) | XN02BGP112E001010304658 | NHSA |
| Upjohn EESV | 国药准字HJ20150620 | 75mg | Category B (乙) | XN02BGP112E001010378724 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213703 | 25mg | Category B (乙) | XN02BGP112E001010379261 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001010379286 | NHSA |
| 广东金城金素制药有限公司 | 国药准字H20233167 | 75mg | Category B (乙) | XN02BGP112E001010381274 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20203550 | 75mg | Category B (乙) | XN02BGP112E001010381661 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243211 | 75mg | Category B (乙) | XN02BGP112E001010383521 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203641 | 75mg | Category B (乙) | XN02BGP112E001010404565 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213765 | 75mg | Category B (乙) | XN02BGP112E001010404647 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213703 | 25mg | Category B (乙) | XN02BGP112E001010479261 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001010479286 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20203550 | 75mg | Category B (乙) | XN02BGP112E001010481661 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243211 | 75mg | Category B (乙) | XN02BGP112E001010483521 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203641 | 75mg | Category B (乙) | XN02BGP112E001010504565 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213703 | 25mg | Category B (乙) | XN02BGP112E001010579261 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001010579286 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20203550 | 75mg | Category B (乙) | XN02BGP112E001010581661 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243211 | 75mg | Category B (乙) | XN02BGP112E001010583521 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203641 | 75mg | Category B (乙) | XN02BGP112E001010604565 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001010679286 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243211 | 75mg | Category B (乙) | XN02BGP112E001010683521 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001010779286 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243211 | 75mg | Category B (乙) | XN02BGP112E001010783521 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001010879286 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243211 | 75mg | Category B (乙) | XN02BGP112E001010883521 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001010979286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001011079286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001011179286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001011279286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001011379286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001011479286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001011579286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20243261 | 150mg | Category B (乙) | XN02BGP112E001011679286 | NHSA |
| 重庆赛维药业有限公司 | 国药准字H20130065 | 25mg | Category B (乙) | XN02BGP112E001020101028 | NHSA |
| 湖南洞庭药业股份有限公司 | 国药准字H20233558 | 150mg | Category B (乙) | XN02BGP112E001020101066 | NHSA |
| Upjohn EESV | 国药准字J20160021 | 75mg | Category B (乙) | XN02BGP112E001020101187 | NHSA |
| 扬子江药业集团南京海陵药业有限公司 | 国药准字H20223587 | 150mg | Category B (乙) | XN02BGP112E001020101748 | NHSA |
| 四川制药制剂有限公司 | 国药准字H20233923 | 150mg | Category B (乙) | XN02BGP112E001020102297 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20213450 | 150mg | Category B (乙) | XN02BGP112E001020102770 | NHSA |
| 亚宝药业集团股份有限公司 | 国药准字H20223958 | 150mg | Category B (乙) | XN02BGP112E001020102987 | NHSA |
| 山东丹红制药有限公司 | 国药准字H20234017 | 150mg | Category B (乙) | XN02BGP112E001020104073 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20243977 | 75mg | Category B (乙) | XN02BGP112E001020104187 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203640 | 150mg | Category B (乙) | XN02BGP112E001020104565 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20253179 | 150mg | Category B (乙) | XN02BGP112E001020104606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213766 | 100mg | Category B (乙) | XN02BGP112E001020104647 | NHSA |
| 广东九瑞科技开发有限公司 | 国药准字H20223713 | 100mg | Category B (乙) | XN02BGP112E001020104658 | NHSA |
| 澳美制药(海南)有限公司 | 国药准字H20243329 | 75mg | Category B (乙) | XN02BGP112E001020105760 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20203041 | 150mg | Category B (乙) | XN02BGP112E001020105847 | NHSA |
| Dr.Reddy's Laboratories Limited | 国药准字HJ20230098 | 150mg | Category B (乙) | XN02BGP112E001020178377 | NHSA |
| Upjohn EESV | 国药准字HJ20150623 | 150mg | Category B (乙) | XN02BGP112E001020178724 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213702 | 50mg | Category B (乙) | XN02BGP112E001020179261 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001020179286 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20223306 | 150mg | Category B (乙) | XN02BGP112E001020180086 | NHSA |
| 大桐制药(中国)有限责任公司 | 国药准字H20253195 | 150mg | Category B (乙) | XN02BGP112E001020180685 | NHSA |
| 广东金城金素制药有限公司 | 国药准字H20233166 | 100mg | Category B (乙) | XN02BGP112E001020181274 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20203551 | 150mg | Category B (乙) | XN02BGP112E001020181661 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213340 | 150mg | Category B (乙) | XN02BGP112E001020182249 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243210 | 100mg | Category B (乙) | XN02BGP112E001020183521 | NHSA |
| 福建省宝诺医药研发有限公司 | 国药准字H20249116 | 150mg | Category B (乙) | XN02BGP112E001020183544 | NHSA |
| 宁波双成药业有限公司 | 国药准字H20243331 | 300mg | Category B (乙) | XN02BGP112E001020184155 | NHSA |
| 湖南洞庭药业股份有限公司 | 国药准字H20233558 | 150mg | Category B (乙) | XN02BGP112E001020201066 | NHSA |
| Upjohn EESV | 国药准字J20160021 | 75mg | Category B (乙) | XN02BGP112E001020201187 | NHSA |
| 扬子江药业集团南京海陵药业有限公司 | 国药准字H20223587 | 150mg | Category B (乙) | XN02BGP112E001020201748 | NHSA |
| 亚宝药业集团股份有限公司 | 国药准字H20223958 | 150mg | Category B (乙) | XN02BGP112E001020202987 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203640 | 150mg | Category B (乙) | XN02BGP112E001020204565 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20253179 | 150mg | Category B (乙) | XN02BGP112E001020204606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213766 | 100mg | Category B (乙) | XN02BGP112E001020204647 | NHSA |
| 澳美制药(海南)有限公司 | 国药准字H20243329 | 75mg | Category B (乙) | XN02BGP112E001020205760 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20203041 | 150mg | Category B (乙) | XN02BGP112E001020205847 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213702 | 50mg | Category B (乙) | XN02BGP112E001020279261 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001020279286 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20223306 | 150mg | Category B (乙) | XN02BGP112E001020280086 | NHSA |
| 广东金城金素制药有限公司 | 国药准字H20233166 | 100mg | Category B (乙) | XN02BGP112E001020281274 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20203551 | 150mg | Category B (乙) | XN02BGP112E001020281661 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213340 | 150mg | Category B (乙) | XN02BGP112E001020282249 | NHSA |
| 福建省宝诺医药研发有限公司 | 国药准字H20249116 | 150mg | Category B (乙) | XN02BGP112E001020283544 | NHSA |
| 湖南洞庭药业股份有限公司 | 国药准字H20233558 | 150mg | Category B (乙) | XN02BGP112E001020301066 | NHSA |
| Upjohn EESV | 国药准字J20160021 | 75mg | Category B (乙) | XN02BGP112E001020301187 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203640 | 150mg | Category B (乙) | XN02BGP112E001020304565 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20253179 | 150mg | Category B (乙) | XN02BGP112E001020304606 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213766 | 100mg | Category B (乙) | XN02BGP112E001020304647 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213702 | 50mg | Category B (乙) | XN02BGP112E001020379261 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001020379286 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20223306 | 150mg | Category B (乙) | XN02BGP112E001020380086 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20203551 | 150mg | Category B (乙) | XN02BGP112E001020381661 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213340 | 150mg | Category B (乙) | XN02BGP112E001020382249 | NHSA |
| 福建省宝诺医药研发有限公司 | 国药准字H20249116 | 150mg | Category B (乙) | XN02BGP112E001020383544 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203640 | 150mg | Category B (乙) | XN02BGP112E001020404565 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213766 | 100mg | Category B (乙) | XN02BGP112E001020404647 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213702 | 50mg | Category B (乙) | XN02BGP112E001020479261 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001020479286 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213340 | 150mg | Category B (乙) | XN02BGP112E001020482249 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203640 | 150mg | Category B (乙) | XN02BGP112E001020504565 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213702 | 50mg | Category B (乙) | XN02BGP112E001020579261 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001020579286 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213340 | 150mg | Category B (乙) | XN02BGP112E001020582249 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20203640 | 150mg | Category B (乙) | XN02BGP112E001020604565 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001020679286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001020779286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001020879286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001020979286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001021079286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001021179286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001021279286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001021379286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001021479286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001021579286 | NHSA |
| 湖南抱抱团药业有限公司 | 国药准字H20247280 | 75mg | Category B (乙) | XN02BGP112E001021679286 | NHSA |
| 重庆赛维药业有限公司 | 国药准字H20130073 | 75mg | Category B (乙) | XN02BGP112E001030101028 | NHSA |
| Upjohn EESV | 国药准字J20160022 | 150mg | Category B (乙) | XN02BGP112E001030101187 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213767 | 150mg | Category B (乙) | XN02BGP112E001030104647 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 75mg | Category B (乙) | XN02BGP112E001030179261 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20223307 | 300mg | Category B (乙) | XN02BGP112E001030180086 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213339 | 75mg | Category B (乙) | XN02BGP112E001030182249 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001030183521 | NHSA |
| 重庆赛维药业有限公司 | 国药准字H20130073 | 75mg | Category B (乙) | XN02BGP112E001030201028 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213767 | 150mg | Category B (乙) | XN02BGP112E001030204647 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 75mg | Category B (乙) | XN02BGP112E001030279261 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213339 | 75mg | Category B (乙) | XN02BGP112E001030282249 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001030283521 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20213767 | 150mg | Category B (乙) | XN02BGP112E001030304647 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 75mg | Category B (乙) | XN02BGP112E001030379261 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213339 | 75mg | Category B (乙) | XN02BGP112E001030382249 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001030383521 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 75mg | Category B (乙) | XN02BGP112E001030479261 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213339 | 75mg | Category B (乙) | XN02BGP112E001030482249 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001030483521 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 75mg | Category B (乙) | XN02BGP112E001030579261 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213339 | 75mg | Category B (乙) | XN02BGP112E001030582249 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001030583521 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 75mg | Category B (乙) | XN02BGP112E001030679261 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20213339 | 75mg | Category B (乙) | XN02BGP112E001030682249 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001030683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001030783521 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 75mg | Category B (乙) | XN02BGP112E001030879261 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001030883521 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 75mg | Category B (乙) | XN02BGP112E001030979261 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001030983521 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213704 | 75mg | Category B (乙) | XN02BGP112E001031079261 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001031983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001032083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001032183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001032283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001032383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001032483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001032583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20234482 | 150mg | Category B (乙) | XN02BGP112E001032683521 | NHSA |
| 重庆赛维药业有限公司 | 国药准字H20130073 | 75mg | Category B (乙) | XN02BGP112E001040101028 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213705 | 100mg | Category B (乙) | XN02BGP112E001040179261 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213705 | 100mg | Category B (乙) | XN02BGP112E001040279261 | NHSA |
| 重庆赛维药业有限公司 | 国药准字H20130073 | 75mg | Category B (乙) | XN02BGP112E001040301028 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213705 | 100mg | Category B (乙) | XN02BGP112E001040379261 | NHSA |
| 重庆赛维药业有限公司 | 国药准字H20130073 | 75mg | Category B (乙) | XN02BGP112E001040401028 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213705 | 100mg | Category B (乙) | XN02BGP112E001040479261 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213705 | 100mg | Category B (乙) | XN02BGP112E001040579261 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213706 | 150mg | Category B (乙) | XN02BGP112E001050179261 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213706 | 150mg | Category B (乙) | XN02BGP112E001050279261 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213706 | 150mg | Category B (乙) | XN02BGP112E001050379261 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213706 | 150mg | Category B (乙) | XN02BGP112E001050479261 | NHSA |
| 石家庄龙泽制药股份有限公司 | 国药准字H20213706 | 150mg | Category B (乙) | XN02BGP112E001050579261 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 12 filings and 6 distinct first applicants.
Generic 11 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 烟台鲁银药业有限公司 | CYHS2504260 | Generic | 2025/12/11 | Not stated by source | CDE |
| 烟台鲁银药业有限公司 | CYHS2504259 | Generic | 2025/12/11 | Not stated by source | CDE |
| 烟台鲁银药业有限公司 | CYHS2504258 | Generic | 2025/12/11 | Not stated by source | CDE |
| 四川制药制剂有限公司 | CYHB2600369 | Supplement | 2026/02/24 | Not stated by source | CDE |
| 成都恒瑞制药有限公司 | CYHS2600422 | Generic | 2026/02/10 | Not stated by source | CDE |
| 浙江普洛康裕制药有限公司 | CYHS2504522 | Generic | 2026/01/01 | Not stated by source | CDE |
| 浙江普洛康裕制药有限公司 | CYHS2504521 | Generic | 2026/01/01 | Not stated by source | CDE |
| 浙江普洛康裕制药有限公司 | CYHS2504520 | Generic | 2026/01/01 | Not stated by source | CDE |
| 辰欣药业股份有限公司 | CYHS2503818 | Generic | 2025/10/29 | Not stated by source | CDE |
| 辰欣药业股份有限公司 | CYHS2503817 | Generic | 2025/10/29 | Not stated by source | CDE |
| 石家庄市华新药业有限责任公司 | CYHS2502144 | Generic | 2025/06/17 | Not stated by source | CDE |
| 石家庄市华新药业有限责任公司 | CYHS2502143 | Generic | 2025/06/17 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 成都恒瑞制药有限公司 | CYHS2600422 | Generic | 2026/02/10 | Not stated by source | CDE |
| 浙江普洛康裕制药有限公司 | CYHS2504522 | Generic | 2026/01/01 | Not stated by source | CDE |
| 浙江普洛康裕制药有限公司 | CYHS2504521 | Generic | 2026/01/01 | Not stated by source | CDE |
| 浙江普洛康裕制药有限公司 | CYHS2504520 | Generic | 2026/01/01 | Not stated by source | CDE |
API registrations
Non-component matches: 25 companies with A status and 9 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 普瑞巴林 | 安徽鼎旺医药有限公司 | Y20260000861 | I | Exact ingredient | 2026/10/26 | CDE |
| 普瑞巴林 | 浙江竹子制药有限公司 | Y20260000563 | I | Exact ingredient | 2026/07/16 | CDE |
| 普瑞巴林 | 万洋衡水制药有限公司 | Y20250001306 | I | Exact ingredient | 2025/12/04 | CDE |
| 普瑞巴林 | 山东立新制药有限公司 | Y20250000894 | I | Exact ingredient | 2025/09/30 | CDE |
| 普瑞巴林 | 浙江普洛家园药业有限公司 | Y20250000865 | I | Exact ingredient | 2025/09/03 | CDE |
| 普瑞巴林 | MSN Pharmachem Private Limited | Y20240000210 | A | Exact ingredient | 2026/05/20 | CDE |
| 普瑞巴林 | Upjohn EESV | Y20230001164 | A | Exact ingredient | 2025/12/29 | CDE |
| 普瑞巴林 | 双鹤药业（商丘）有限责任公司 | Y20230000632 | A | Exact ingredient | 2025/04/07 | CDE |
| 普瑞巴林 | Hikal Limited | Y20220000761 | A | Exact ingredient | 2025/04/22 | CDE |
| 普瑞巴林 | 山东立新制药有限公司 | Y20220000631 | I | Exact ingredient | 2022/09/08 | CDE |
| 普瑞巴林 | Vasudha Pharma Chem Limited | Y20210000819 | I | Exact ingredient | 2021/12/21 | CDE |
| 普瑞巴林 | 湖南赛隆药业有限公司 | Y20210000955 | A | Exact ingredient | 2024/03/07 | CDE |
| 普瑞巴林 | 东北制药集团股份有限公司 | Y20210000638 | A | Exact ingredient | 2024/01/24 | CDE |
| 普瑞巴林 | MSN Life Sciences Private Limited Unit-Ⅲ | Y20200001043 | A | Exact ingredient | 2025/08/16 | CDE |
| 普瑞巴林 | Divi’s Laboratories Limited | Y20210000256 | A | Exact ingredient | 2024/01/17 | CDE |
| 普瑞巴林 | Dr.Reddy‘s Laboratories Limited | Y20210000101 | I | Exact ingredient | 2023/12/20 | CDE |
| 普瑞巴林 | DR. REDDYS LABORATORIES LIMITED | Y20200000823 | A | Exact ingredient | 2026/07/11 | CDE |
| 普瑞巴林 | 江苏慧聚药业股份有限公司 | Y20190000654 | A | Exact ingredient | 2026/04/24 | CDE |
| 普瑞巴林 | 石药集团欧意药业有限公司 | Y20190021404 | A | Exact ingredient | 2026/03/17 | CDE |
| 普瑞巴林 | 石家庄龙泽制药股份有限公司 | Y20190021315 | A | Exact ingredient | 2026/04/20 | CDE |
| 普瑞巴林 | 重庆赛维药业有限公司 | Y20190009848 | A | Exact ingredient | — | CDE |
| 普瑞巴林 | 重庆赛维药业有限公司 | Y20190000198 | A | Exact ingredient | 2025/09/25 | CDE |
| 普瑞巴林 | 奥锐特药业股份有限公司 | Y20190000368 | A | Exact ingredient | 2026/08/14 | CDE |
| 普瑞巴林 | 浙江天宇药业股份有限公司 | Y20180001381 | A | Exact ingredient | 2026/01/13 | CDE |
| 普瑞巴林 | 浙江美诺华药物化学有限公司 | Y20180001513 | A | Exact ingredient | 2025/07/18 | CDE |
| 普瑞巴林 | 江苏恩华药业股份有限公司 | Y20170001560 | A | Exact ingredient | 2023/07/14 | CDE |
| 普瑞巴林 | 双鹤药业（商丘）有限责任公司 | Y20170001559 | A | Exact ingredient | 2023/05/11 | CDE |
| 普瑞巴林 | 浙江华海药业股份有限公司 | Y20170001497 | A | Exact ingredient | 2023/08/16 | CDE |
| 普瑞巴林 | 国药集团宜宾制药有限责任公司 | Y20170001200 | A | Exact ingredient | 2024/04/26 | CDE |
| 普瑞巴林 | Hetero Drugs Limited, Unit- IX | Y20170001183 | A | Exact ingredient | 2025/12/06 | CDE |
| 普瑞巴林 | 廊坊高博京邦制药有限公司 | Y20170001167 | A | Exact ingredient | 2022/09/08 | CDE |
| 普瑞巴林 | Optimus Drugs Pvt Ltd | Y20170001044 | I | Exact ingredient | — | CDE |
| 普瑞巴林 | SUN PHARMACEUTICAL INDUSTRIES LTD | Y20170000832 | A | Exact ingredient | 2022/09/05 | CDE |
| 普瑞巴林 | 山东安弘制药有限公司 | Y20170000821 | A | Exact ingredient | 2026/10/30 | CDE |
| 普瑞巴林 | Alembic Pharmaceuticals Ltd. | Y20170000779 | A | Exact ingredient | 2026/03/19 | CDE |
| 普瑞巴林 | CTX Lifesciences Pvt. Ltd. | Y20170000558 | A | Exact ingredient | 2026/08/22 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/09/04Accepted
湖南抱抱团药业有限公司;湖南赛隆药业（长沙）有限公司
CYHB2601685
Fact date: 2026/09/04 · Site observation date: 2026/10/22
View source ↗ -
2026/09/04Accepted
湖南抱抱团药业有限公司;湖南赛隆药业（长沙）有限公司
CYHB2601684
Fact date: 2026/09/04 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Pregabalin Capsules
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy